Subjects with DFU will receive Standard of care (SOC) up to 15 days and then will be randomized to one of the three arms: GSK1278863 + SOC, or SOC only, or placebo + SOC with ratio of 12:2:2. Doses for the cohorts in Part B will be determined from safety, tolerability and PK data from Part A. subjects will first be given a single application of GSK1278863 or placebo at the dose chosen for that cohort, followed by a 7-day washout period, and then repeat applications for 14 days, starting on Day 8.

Subjects with DFU will receive Standard of care (SOC) up to 15 days and then will be randomized to one of the three arms: GSK1278863 + SOC, or SOC only, or placebo + SOC with ratio of 12:2:2. Doses for the cohorts in Part B will be determined from safety, tolerability and PK data from Part A. subjects will first be given a single application of GSK1278863 or placebo at the dose chosen for that cohort, followed by a 7-day washout period, and then repeat applications for 14 days, starting on Day 8.

Subjects with DFU will receive Standard of care (SOC) up to 15 days and then will be randomized to one of the three arms: GSK1278863 + SOC, or SOC only, or placebo + SOC with ratio of 12:2:2. Doses for the cohorts in Part B will be determined from safety, tolerability and PK data from Part A. subjects will first be given a single application of GSK1278863 or placebo at the dose chosen for that cohort, followed by a 7-day washout period, and then repeat applications for 14 days, starting on Day 8.

White to off-white smooth ointment for topical application as single or repeat doses.

Vital sign measurements included systolic blood pressure (SBP) and diastolic blood pressure (DBP). Vital signs were measured after the participants rested in a supine or semi-supine position for 5 minutes prior to the procedure. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). When a high or low value was reported, all values are presented for that time point and parameter.

Vital sign measurements included systolic blood pressure (SBP) and diastolic blood pressure (DBP). Vital signs were measured after the participants rested in a supine or semi-supine position for 5 minutes prior to the procedure. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). When a high or low value was reported, all values are presented for that time point and parameter.

A brief physical assessments of the skin, lungs, cardiovascular system, and abdomen (liver and spleen) were planned to be performed by qualified licensed, medical professional (i.e., physician, physician assistant, or nurse practitioner) but was not performed.Since data was not collected, no analysis was performed.

A brief physical assessments of the skin, lungs, cardiovascular system, and abdomen (liver and spleen) were planned to be performed by qualified licensed, medical professional (i.e., physician, physician assistant, or nurse practitioner) but was not performed. Since data was not collected, no analysis was performed.

Hematology parameters assessed were: platelet count, red blood cell count, white blood cell count, hemoglobin, reticulocyte count, hematocrit, absolute neutrophil count (ANC), monocytes, lymphocytes, eosinophils, basophils, mean corpuscular volume, mean corpuscular hemoglobin, and mean corpuscular hemoglobin concentration. When a high or low value was reported, all values are presented for that time point and parameter.

Hematology parameters assessed were: platelet count, red blood cell count, white blood cell count, hemoglobin, reticulocyte count, hematocrit, neutrophils, monocytes, lymphocytes, eosinophils, basophils, mean corpuscular volume, mean corpuscular hemoglobin, and mean corpuscular hemoglobin concentration. When a high or low value was reported, all values are presented for that time point and parameter.

Chemistry parameters assessed were: Blood urea nitrogen (BUN), creatinine, fasting glucose, sodium, creatine phosphokinase (CPK), potassium, chloride, total carbon dioxide (CO2), calcium, glycosylated hemoglobin (HbA1C), Aspartate aminotransferase (AST), Alanine aminotransferase (ALT), Gamma glutamyltransferase (GGT), Alkaline phosphatase (ALP), High sensitivity C-reactive protein (hsCRP), total and direct bilirubin, uric acid, albumin and total protein. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). When a high or low value was reported, all values are presented for that time point and parameter.

Chemistry parameters assessed were: Blood urea nitrogen (BUN), creatinine, fasting glucose, sodium, creatine phosphokinase (CPK), potassium, chloride, total carbon dioxide (CO2), calcium, glycosylated hemoglobin (HbA1C), Aspartate aminotransferase (AST), Alanine aminotransferase (ALT), Gamma glutamyltransferase (GGT), Alkaline phosphatase (ALP), High sensitivity C-reactive protein (hsCRP), total and direct bilirubin, uric acid, albumin and total protein. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). When a high or low value was reported, all values are presented for that time point and parameter.

The pharmacokinetic (PK) parameters were calculated by standard non-compartmental analysis according to current working practices and using WinNonlin Version 5.2 or higher. All calculations of non-compartmental parameters were based on actual sampling times. Cmax could not be determined as data was below the limit of quantification.

The pharmacokinetic parameters were calculated by standard non-compartmental analysis according to current working practices and using WinNonlin Version 5.2 or higher. All calculations of non-compartmental parameters were based on actual sampling times. Cmax could not be determined as data was below the limit of quantification.

The pharmacokinetic parameters were calculated by standard non-compartmental analysis according to current working practices and using WinNonlin Version 5.2 or higher. All calculations of non-compartmental parameters were based on actual sampling times. Tmax could not be determined as data was below the limit of quantification.

The pharmacokinetic parameters were calculated by standard non-compartmental analysis according to current working practices and using WinNonlin Version 5.2 or higher. All calculations of non-compartmental parameters were based on actual sampling times. Tmax could not be determined as data was below the limit of quantification.

The pharmacokinetic parameters were calculated by standard non-compartmental analysis according to current working practices and using WinNonlin Version 5.2 or higher. All calculations of non-compartmental parameters were based on actual sampling times. t1/2 could not be determined as data was below the limit of quantification.

The pharmacokinetic parameters were calculated by standard non-compartmental analysis according to current working practices and using WinNonlin Version 5.2 or higher. All calculations of non-compartmental parameters were based on actual sampling times. t1/2 could not be determined as data was below the limit of quantification.

The pharmacokinetic parameters were calculated by standard non-compartmental analysis according to current working practices and using WinNonlin Version 5.2 or higher. All calculations of non-compartmental parameters were based on actual sampling times. Tlag could not be determined as data was below the limit of quantification.

The pharmacokinetic parameters were calculated by standard non-compartmental analysis according to current working practices and using WinNonlin Version 5.2 or higher. All calculations of non-compartmental parameters were based on actual sampling times. Tlag could not be determined as data was below the limit of quantification.

The pharmacokinetic parameters were calculated by standard non-compartmental analysis according to current working practices and using WinNonlin Version 5.2 or higher. All calculations of non-compartmental parameters were based on actual sampling times. AUC (0-inf) could not be determined as data was below the limit of quantification.

The pharmacokinetic parameters were calculated by standard non-compartmental analysis according to current working practices and using WinNonlin Version 5.2 or higher. All calculations of non-compartmental parameters were based on actual sampling times. AUC (0-inf) could not be determined as data was below the limit of quantification.

The pharmacokinetic parameters were calculated by standard non-compartmental analysis according to current working practices and using WinNonlin Version 5.2 or higher. All calculations of non-compartmental parameters were based on actual sampling times. AUC (0-t) could not be determined as data was below the limit of quantification.

The pharmacokinetic parameters were calculated by standard non-compartmental analysis according to current working practices and using WinNonlin Version 5.2 or higher. All calculations of non-compartmental parameters were based on actual sampling times. AUC (0-t) could not be determined as data was below the limit of quantification.

Healthy participants were enrolled. Participants were administered a single dose of treatment A=0.3 milligram (mg) GSK1278863 on intact skin in Period 1 and a single dose of treatment B=3 mg GSK1278863 on intact skin in Period 2. There was a wash out period of 10 days between the two periods.

Participants with DFU were administered 0.1 percent of 25 milligrams per square centimeter (mg/cm^2) GSK1278863 on intact skin in Period 1 followed by a wash-out period of at least 10 days. Participants were then administered a single dose of 0.1 percent of 25 mg/cm^2 on wounded skin in Period 2.

Participants with DFU were administered a single dose of 1 percent of 25 mg/cm^2 GSK1278863 on wounded skin.

A single dose of 1 percent of 100 mg/cm^2 GSK1278863 was applied directly to wounded skin in Period 1, followed by application of a single dose of 1 percent of 100 mg/cm^2 GSK1278863 to intact skin. There was a wash-out period of at least 10 days between the two dosing periods.

Participants with DFU received once daily placebo application directly to the wounded skin for 14 days along with standard of care therapy.

Participants with DFU received once daily application of 1 percent of 100 mg/cm^2 GSK1278863 to wounded skin for 14 days along with standard of care treatment.

Participants with DFU continued to receive daily application of standard of care wound treatment for 14 days.

Participants with DFU were administered 0.1 percent of 25 milligrams per square centimeter (mg/cm^2) GSK1278863 on intact skin in Period 1 followed by a wash-out period of at least 10 days. Participants were then administered a single dose of 0.1 percent of 25 mg/cm^2 on wounded skin in Period 2.

Participants with DFU were administered a single dose of 1 percent of 25 mg/cm^2 GSK1278863 on wounded skin.

A single dose of 1 percent of 100 mg/cm^2 GSK1278863 was applied directly to wounded skin in Period 1, followed by application of a single dose of 1 percent of 100 mg/cm^2 GSK1278863 to intact skin. There was a wash-out period of at least 10 days between the two dosing periods.

Participants with DFU were administered 0.1 percent of 25 milligrams per square centimeter (mg/cm^2) GSK1278863 on intact skin in Period 1 followed by a wash-out period of at least 10 days. Participants were then administered a single dose of 0.1 percent of 25 mg/cm^2 on wounded skin in Period 2.

Participants with DFU were administered a single dose of 1 percent of 25 mg/cm^2 GSK1278863 on wounded skin.

A single dose of 1 percent of 100 mg/cm^2 GSK1278863 was applied directly to wounded skin in Period 1, followed by application of a single dose of 1 percent of 100 mg/cm^2 GSK1278863 to intact skin. There was a wash-out period of at least 10 days between the two dosing periods.

Participants with DFU were administered 0.1 percent of 25 milligrams per square centimeter (mg/cm^2) GSK1278863 on intact skin in Period 1 followed by a wash-out period of at least 10 days. Participants were then administered a single dose of 0.1 percent of 25 mg/cm^2 on wounded skin in Period 2.

Participants with DFU were administered a single dose of 1 percent of 25 mg/cm^2 GSK1278863 on wounded skin.

A single dose of 1 percent of 100 mg/cm^2 GSK1278863 was applied directly to wounded skin in Period 1, followed by application of a single dose of 1 percent of 100 mg/cm^2 GSK1278863 to intact skin. There was a wash-out period of at least 10 days between the two dosing periods.

Participants with DFU were administered 0.1 percent of 25 milligrams per square centimeter (mg/cm^2) GSK1278863 on intact skin in Period 1 followed by a wash-out period of at least 10 days. Participants were then administered a single dose of 0.1 percent of 25 mg/cm^2 on wounded skin in Period 2.

Participants with DFU were administered a single dose of 1 percent of 25 mg/cm^2 GSK1278863 on wounded skin.

A single dose of 1 percent of 100 mg/cm^2 GSK1278863 was applied directly to wounded skin in Period 1, followed by application of a single dose of 1 percent of 100 mg/cm^2 GSK1278863 to intact skin. There was a wash-out period of at least 10 days between the two dosing periods.

Healthy participants were enrolled. Participants were administered a single dose of treatment A=0.3 milligram (mg) GSK1278863 on intact skin in Period 1 and a single dose of treatment B=3 mg GSK1278863 on intact skin in Period 2. There was a wash out period of 10 days between the two periods.

Participants with DFU were administered 0.1 percent of 25 milligrams per square centimeter (mg/cm^2) GSK1278863 on intact skin in Period 1 followed by a wash-out period of at least 10 days. Participants were then administered a single dose of 0.1 percent of 25 mg/cm^2 on wounded skin in Period 2.

Participants with DFU were administered a single dose of 1 percent of 25 mg/cm^2 GSK1278863 on wounded skin.

A single dose of 1 percent of 100 mg/cm^2 GSK1278863 was applied directly to wounded skin in Period 1, followed by application of a single dose of 1 percent of 100 mg/cm^2 GSK1278863 to intact skin. There was a wash-out period of at least 10 days between the two dosing periods.

A single dose of 1 percent of 100 mg/cm^2 GSK1278863 was applied directly to wounded skin in Period 1, followed by application of a single dose of 1 percent of 100 mg/cm^2 GSK1278863 to intact skin. There was a wash-out period of at least 10 days between the two dosing periods.

A single dose of 1 percent of 100 mg/cm^2 GSK1278863 was applied directly to wounded skin in Period 1, followed by application of a single dose of 1 percent of 100 mg/cm^2 GSK1278863 to intact skin. There was a wash-out period of at least 10 days between the two dosing periods.

A single dose of 1 percent of 100 mg/cm^2 GSK1278863 was applied directly to wounded skin in Period 1, followed by application of a single dose of 1 percent of 100 mg/cm^2 GSK1278863 to intact skin. There was a wash-out period of at least 10 days between the two dosing periods.

A single dose of 1 percent of 100 mg/cm^2 GSK1278863 was applied directly to wounded skin in Period 1, followed by application of a single dose of 1 percent of 100 mg/cm^2 GSK1278863 to intact skin. There was a wash-out period of at least 10 days between the two dosing periods.

A single dose of 1 percent of 100 mg/cm^2 GSK1278863 was applied directly to wounded skin in Period 1, followed by application of a single dose of 1 percent of 100 mg/cm^2 GSK1278863 to intact skin. There was a wash-out period of at least 10 days between the two dosing periods.